![](/images/graphics-bg.png)
Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions
Joint Authors
Canbay, Ali
Bose, Katrin
Franck, Caspar
Müller, Meike N.
Link, Alexander
Venerito, Marino
Source
Gastroenterology Research and Practice
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-07-13
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Perioperative chemotherapy improves overall survival in patients with oesophagogastric adenocarcinoma (OAC) and locoregional disease.
The mainstay of perioperative chemotherapy in these patients is a platinum/fluoropyrimidine combination.
The phase III FLOT4 trial has shown that the FLOT triplet regimen (oxaliplatin, infusional 5-FU, and docetaxel) improves the outcome of patients with OAC and locoregional disease as compared to the ECF triplet (epirubicin, cisplatin, and infusional 5-FU).
Targeted therapies have currently no role in the perioperative setting for the treatment of patients with OAC.
For patients with oligometastatic disease, upfront gastrectomy followed by chemotherapy did not show any survival benefit compared with chemotherapy alone and thus should be discouraged.
Whether surgery should be offered to patients with metastatic OAC achieving a systemic control after upfront chemotherapy is under scrutiny in the phase III FLOT5/Renaissance trial.
After neoadjuvant treatment, lymph node status but not pathologic tumor response is an independent factor in the prediction of overall survival.
Growing evidence suggests that perioperative chemotherapy may be associated with an increased mortality risk in patients with microsatellite instable (MSI)/mismatch repair-deficient (MMRD) adenocarcinoma, thus validating poor responsiveness to chemotherapy in MSI patients with locoregional disease.
American Psychological Association (APA)
Bose, Katrin& Franck, Caspar& Müller, Meike N.& Canbay, Ali& Link, Alexander& Venerito, Marino. 2017. Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions. Gastroenterology Research and Practice،Vol. 2017, no. 2017, pp.1-6.
https://search.emarefa.net/detail/BIM-1156472
Modern Language Association (MLA)
Bose, Katrin…[et al.]. Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions. Gastroenterology Research and Practice No. 2017 (2017), pp.1-6.
https://search.emarefa.net/detail/BIM-1156472
American Medical Association (AMA)
Bose, Katrin& Franck, Caspar& Müller, Meike N.& Canbay, Ali& Link, Alexander& Venerito, Marino. Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions. Gastroenterology Research and Practice. 2017. Vol. 2017, no. 2017, pp.1-6.
https://search.emarefa.net/detail/BIM-1156472
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1156472